BCL2 and B-cell chronic lymphocytic leukemia: ncRNAs could be screened for therapy decision; for example, low levels of miR-181a and miR-181b predict therapy resistance, and their upregulation enhances drug sensitivity in primary CLL cell cells through direct targeting of the anti-apoptotic genes BCL-2 and MCL1.